{"date":"2026-09-21","count":8,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6976-2026-09-21-1841-hlzlxy","company_id":"6976","company":"育世博-KY","market":"興櫃","industry":"生技醫療","date":"2026-09-21","time":"18:41:48","subject":"代重要子公司育世博生物科技股份有限公司公告研發中之ADC新藥ACE723向台灣TFDA提出人體臨床試驗審查申請","clause":"第8款","fact_date":"2026-09-21","cite_as":"公開資訊觀測站重大訊息：育世博-KY（6976），2026-09-21 18:41，「代重要子公司育世博生物科技股份有限公司公告研發中之ADC新藥ACE723向台灣TFDA提出人體臨床試驗審查申請」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2026-09-21-1808-10jca0t","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2026-09-21","time":"18:08:21","subject":"本公司受邀參加凱基證券舉辦之法人說明會","clause":"第12款","fact_date":"2026-09-30","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2026-09-21 18:08，「本公司受邀參加凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-09-21-1805-10daxhw","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-09-21","time":"18:05:58","subject":"本公司115年9月29日受邀參加元大證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2026-09-29","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-09-21 18:05，「本公司115年9月29日受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2026-09-21-1804-10jca0t","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2026-09-21","time":"18:04:17","subject":"本公司受邀參加凱基證券舉辦之法人說明會","clause":"第12款","fact_date":"2026-09-30","cite_as":"公開資訊觀測站重大訊息：大江（8436），2026-09-21 18:04，「本公司受邀參加凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8436-2026-09-21-1802-hk2f6k","company_id":"8436","company":"大江","market":"上櫃","industry":"生技醫療","date":"2026-09-21","time":"18:02:44","subject":"公告本公司買回庫藏股執行完畢","clause":"第35款","fact_date":"2026-09-21","cite_as":"公開資訊觀測站重大訊息：大江（8436），2026-09-21 18:02，「公告本公司買回庫藏股執行完畢」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-09-21-1754-1qwcpzz","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-09-21","time":"17:54:09","subject":"本公司新藥CBL-514注射劑用於治療竇根氏症之二期臨床試驗取得最終統計結果，其主要療效指標在統計上達到顯著有效意義。","clause":"第10款","fact_date":"2026-09-21","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-09-21 17:54，「本公司新藥CBL-514注射劑用於治療竇根氏症之二期臨床試驗取得最終統計結果，其主要療效指標在統計上達到顯著有效意義。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6734-2026-09-21-1647-1o6dasn","company_id":"6734","company":"安盛生","market":"興櫃","industry":"生技醫療","date":"2026-09-21","time":"16:47:57","subject":"公告本公司訂定115年第二次現金增資發行新股認股基準日等相關事宜","clause":"第9款","fact_date":"2026-09-21","cite_as":"公開資訊觀測站重大訊息：安盛生（6734），2026-09-21 16:47，「公告本公司訂定115年第二次現金增資發行新股認股基準日等相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6885-2026-09-21-0311-d0cy7z","company_id":"6885","company":"全福生技","market":"上市","industry":"生技醫療","date":"2026-09-21","time":"03:11:51","subject":"公告本公司開發中新藥BRM424治療神經營養性角膜炎第II期人體臨床試驗初步結果(Topline Results)。","clause":"第10款","fact_date":"2026-09-19","cite_as":"公開資訊觀測站重大訊息：全福生技（6885），2026-09-21 03:11，「公告本公司開發中新藥BRM424治療神經營養性角膜炎第II期人體臨床試驗初步結果(Topline Results)。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}